Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Jillian, Gardell"'
Autor:
Mikayla C. Lopes, Nicholas A. DaSilva, Benjamin A. Rabinowitz, Jillian Gardell, Steven C. Katz, David C. Rowley, Prajna Guha
Publikováno v:
Oncogene. 40:693-704
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that proliferate in the setting of cancer and have potent immunosuppressive functions hindering anti-tumor immunity. Here we establish that the immunolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::11b2fea25fb94fe77ce97f9780648835
https://doi.org/10.1038/s41388-020-01559-7
https://doi.org/10.1038/s41388-020-01559-7
Autor:
Prajna, Guha, Jillian, Gardell, Benjamin, Rabinowitz, Mikayla, Lopes, Nicholas A, DaSilva, David, Rowley, Steven C, Katz
Publikováno v:
Oncogene. 40(3)
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells that proliferate in the setting of cancer and have potent immunosuppressive functions hindering anti-tumor immunity. Here we establish that the immunolo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::56e538ea30b48f6115d5eb173f253cf1
https://pubmed.ncbi.nlm.nih.gov/33230244
https://pubmed.ncbi.nlm.nih.gov/33230244
Autor:
George Miller, Steven C. Katz, Prajna Guha, Marissa Cunetta, N. Joseph Espat, Josephine Darpolor, Jillian Gardell, Richard P. Junghans, Matthew Lima
Publikováno v:
Oncogene. 38:533-548
Immunosuppressive myeloid-derived suppressor cells (MDSC) subvert antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T). Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC) pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::eb68aabecd5d0f93dcbbd5f1dead5dfe
https://doi.org/10.1038/s41388-018-0449-z
https://doi.org/10.1038/s41388-018-0449-z
Autor:
Prajna, Guha, Jillian, Gardell, Josephine, Darpolor, Marissa, Cunetta, Matthew, Lima, George, Miller, N Joseph, Espat, Richard P, Junghans, Steven C, Katz
Publikováno v:
Oncogene. 38(4)
Immunosuppressive myeloid-derived suppressor cells (MDSC) subvert antitumor immunity and limit the efficacy of chimeric antigen receptor T cells (CAR-T). Previously, we reported that the GM-CSF/JAK2/STAT3 axis drives liver-associated MDSC (L-MDSC) pr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::dd60bfeb83e8b382807e9ca8801d83db
https://pubmed.ncbi.nlm.nih.gov/30158673
https://pubmed.ncbi.nlm.nih.gov/30158673
Publikováno v:
The Journal of Immunology. 200:46.13-46.13
Liver is a tolerogenic organ and has variety of immune cells resulting in a profoundly immunosuppressive space. We recently reported that GM-CSF/JAK2/STAT3 axis drives liver myeloid suppressor cell (L-MDSC) proliferation and STAT3 inhibition causes a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::62f3ae5642e4d54c4d49dd4eadd2d985
https://doi.org/10.4049/jimmunol.200.supp.46.13
https://doi.org/10.4049/jimmunol.200.supp.46.13
Autor:
Jillian Gardell, Prajna Guha, Marissa Cunetta, Matthew Lima, Josephine Darpolor, N. Joseph Espat, Richard P. Junghans, Steven C Katz
Publikováno v:
The Journal of Immunology. 198:198.13-198.13
Myeloid derived suppressor cells (MDSC) subvert anti-tumor immunity. Previously we reported that the GM-CSF/ JAK2/STAT3 axis drives liver MDSC (L-MDSC) proliferation and CAR-T suppression. We hypothesized that STAT3 supports L-MDSC survival and suppr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::68b3d87353d2db793e8284d8ebef3adf
https://doi.org/10.4049/jimmunol.198.supp.198.13
https://doi.org/10.4049/jimmunol.198.supp.198.13
Autor:
Steven J. Katz, Matthew Lima, Prajna Guha, N J. Espat, Zhi Liu, Josephine Darpolor, Gary Point, Marissa Cunetta, Jillian Gardell
Publikováno v:
Cancer Research. 76:2213-2213
We previously tested the efficacy of chimeric antigen receptor T cell (CAR-T) treatment via hepatic artery infusion in a phase I clinical trial. Though these results were promising, our current protocol for hepatic immunotherapy for metastasis (HITM)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9b4f4ddaac1689ef3b2e7bbe523a216b
https://doi.org/10.1158/1538-7445.am2016-2213
https://doi.org/10.1158/1538-7445.am2016-2213